Methods of treating retinitis pigmentosa using nucleic acids encoding RDCVF1 or RDCVF2
US8957043B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jun 4, 2013 |
| Grant date | Feb 17, 2015 |
| Priority date | — |
| Expiry date | Jun 4, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/47
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are methods and compositions for early diagnosis, monitoring and treatment of retinal dystrophy, age-related macular degeneration, Bardet-Biedel syndrome, Bassen-kornzweig syndrome, best disease, choroidema, gyrate atrophy, congenital amourosis, refsun syndrome, stargardt disease and Usher syndrome. In particular, the invention relates to a protein, termed “Rdcvf1,” that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with nonsufferers, antibodies which recognize this protein, and methods for diagnosing such conditions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.